These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 7837388)
1. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. Bonadonna G; Zambetti M; Valagussa P JAMA; 1995 Feb; 273(7):542-7. PubMed ID: 7837388 [TBL] [Abstract][Full Text] [Related]
2. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. Buzzoni R; Bonadonna G; Valagussa P; Zambetti M J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555 [TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. Bonadonna G; Zambetti M; Moliterni A; Gianni L; Valagussa P J Clin Oncol; 2004 May; 22(9):1614-20. PubMed ID: 15117983 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M; J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617 [TBL] [Abstract][Full Text] [Related]
6. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. Silvestrini R; Luisi A; Zambetti M; Cipriani S; Valagussa P; Bonadonna G; Daidone MG Int J Cancer; 2000 Aug; 87(3):405-11. PubMed ID: 10897047 [TBL] [Abstract][Full Text] [Related]
7. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J; J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969 [TBL] [Abstract][Full Text] [Related]
8. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. Fisher B; Jeong JH; Anderson S; Wolmark N J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638 [TBL] [Abstract][Full Text] [Related]
9. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965 [TBL] [Abstract][Full Text] [Related]
10. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma. Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820 [TBL] [Abstract][Full Text] [Related]
11. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L; J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. Hsieh CI; Liu MC; Cheng SH; Liu TW; Chen CM; Chen CM; Tsou MH; Huang AT Am J Clin Oncol; 2000 Apr; 23(2):122-7. PubMed ID: 10776970 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. Bonadonna G; Valagussa P; Moliterni A; Zambetti M; Brambilla C N Engl J Med; 1995 Apr; 332(14):901-6. PubMed ID: 7877646 [TBL] [Abstract][Full Text] [Related]
15. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study. Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study. Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89. Ejlertsen B; Mouridsen HT; Jensen MB Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334 [TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial. Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818 [TBL] [Abstract][Full Text] [Related]
20. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E; Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]